These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 11069197)

  • 1. Response to alendronate in osteoporosis after previous treatment with etidronate.
    Fairney A; Kyd P; Thomas E; Wilson J
    Osteoporos Int; 2000; 11(7):621-5. PubMed ID: 11069197
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Predicting subsequent bone density response to intermittent cyclical therapy with etidronate from initial density response in patients with osteoporosis.
    Crilly RG; Sebaldt RJ; Hodsman AB; Adachi JD; Brown JP; Goldsmith CH; Hanley DA; Olszynski WO; Ste-Marie LG; Stephenson GF
    Osteoporos Int; 2000; 11(7):607-14. PubMed ID: 11069195
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Alendronate increases spine and hip bone mineral density in women with postmenopausal osteoporosis who failed to respond to intermittent cyclical etidronate.
    Watts NB; Becker P
    Bone; 1999 Jan; 24(1):65-8. PubMed ID: 9916786
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Alendronate and indapamide alone or in combination in the management of hypercalciuria associated with osteoporosis: a randomized controlled trial of two drugs and three treatments.
    Giusti A; Barone A; Pioli G; Girasole G; Siccardi V; Palummeri E; Bianchi G
    Nephrol Dial Transplant; 2009 May; 24(5):1472-7. PubMed ID: 19075192
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of effect of treatment with etidronate and alendronate on lumbar bone mineral density in elderly women with osteoporosis.
    Iwamoto J; Takeda T; Sato Y; Uzawa M
    Yonsei Med J; 2005 Dec; 46(6):750-8. PubMed ID: 16385649
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effectiveness of alendronate and etidronate in the treatment of osteoporosis in men: a prospective observational study.
    Olszynski WP; Davison KS; Ioannidis G; Brown JP; Hanley DA; Josse RG; Murray TM; Papaioannou A; Sebaldt RJ; Tenenhouse AM; Petrie A; Goldsmith CH; Adachi JD
    Osteoporos Int; 2006 Feb; 17(2):217-24. PubMed ID: 15997420
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Early response to alendronate after treatment with etidronate in postmenopausal women with osteoporosis.
    Iwamoto J; Takeda T; Ichimura S; Uzawa M
    Keio J Med; 2003 Jun; 52(2):113-9. PubMed ID: 12862363
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of cyclical etidronate with alfacalcidol on lumbar bone mineral density, bone resorption, and back pain in postmenopausal women with osteoporosis.
    Iwamoto J; Takeda T; Ichimura S; Matsu K; Uzawa M
    J Orthop Sci; 2003; 8(4):532-7. PubMed ID: 12898306
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A comparison of continuous alendronate, cyclical alendronate and cyclical etidronate with calcitriol in the treatment of postmenopausal vertebral osteoporosis: a randomized controlled trial.
    Sahota O; Fowler I; Blackwell PJ; Lawson N; Cawte SA; San P; Masud T; Hosking DJ
    Osteoporos Int; 2000; 11(11):959-66. PubMed ID: 11193249
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cyclical etidronate plus ergocalciferol prevents glucocorticoid-induced bone loss in postmenopausal women.
    Diamond T; McGuigan L; Barbagallo S; Bryant C
    Am J Med; 1995 May; 98(5):459-63. PubMed ID: 7733124
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment with once-weekly alendronate 70 mg compared with once-weekly risedronate 35 mg in women with postmenopausal osteoporosis: a randomized double-blind study.
    Rosen CJ; Hochberg MC; Bonnick SL; McClung M; Miller P; Broy S; Kagan R; Chen E; Petruschke RA; Thompson DE; de Papp AE;
    J Bone Miner Res; 2005 Jan; 20(1):141-51. PubMed ID: 15619680
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative efficacy and safety study of etidronate and alendronate in postmenopausal osteoporosis. effect of adding hormone replacement therapy.
    Cortet B; Béra-Louville A; Gauthier P; Gauthier A; Marchandise X; Delcambre B
    Joint Bone Spine; 2001 Oct; 68(5):410-5. PubMed ID: 11707007
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A cost effectiveness analysis of calcium and vitamin D supplementation, etidronate, and alendronate in the prevention of vertebral fractures in women treated with glucocorticoids.
    Buckley LM; Hillner BE
    J Rheumatol; 2003 Jan; 30(1):132-8. PubMed ID: 12508402
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Secondary hyperparathyroidism due to hypovitaminosis D affects bone mineral density response to alendronate in elderly women with osteoporosis: a randomized controlled trial.
    Barone A; Giusti A; Pioli G; Girasole G; Razzano M; Pizzonia M; Palummeri E; Bianchi G
    J Am Geriatr Soc; 2007 May; 55(5):752-7. PubMed ID: 17493196
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of cyclical etidronate combined with calcitriol versus cyclical etidronate alone on spine and femoral neck bone mineral density in postmenopausal osteoporotic women.
    Masud T; Mulcahy B; Thompson AV; Donnelly S; Keen RW; Doyle DV; Spector TD
    Ann Rheum Dis; 1998 Jun; 57(6):346-9. PubMed ID: 9771208
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A four-year randomized controlled trial of hormone replacement and bisphosphonate, alone or in combination, in women with postmenopausal osteoporosis.
    Wimalawansa SJ
    Am J Med; 1998 Mar; 104(3):219-26. PubMed ID: 9552083
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment with alendronate plus calcium, alendronate alone, or calcium alone for postmenopausal low bone mineral density.
    Bonnick S; Broy S; Kaiser F; Teutsch C; Rosenberg E; DeLucca P; Melton M
    Curr Med Res Opin; 2007 Jun; 23(6):1341-9. PubMed ID: 17594775
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A comparison of the effect of risedronate and etidronate on lumbar bone mineral density in Japanese patients with osteoporosis: a randomized controlled trial.
    Fukunaga M; Kushida K; Kishimoto H; Shiraki M; Taketani Y; Minaguchi H; Inoue T; Morita R; Morii H; Yamamoto K; Ohashi Y; Orimo H;
    Osteoporos Int; 2002 Dec; 13(12):971-9. PubMed ID: 12459940
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A comparison of the effect of alendronate and risedronate on bone mineral density in postmenopausal women with osteoporosis: 24-month results from FACTS-International.
    Reid DM; Hosking D; Kendler D; Brandi ML; Wark JD; Marques-Neto JF; Weryha G; Verbruggen N; Hustad CM; Mahlis EM; Melton ME
    Int J Clin Pract; 2008 Apr; 62(4):575-84. PubMed ID: 18324951
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Response rate of bone mineral density to teriparatide in postmenopausal women with osteoporosis.
    Gallagher JC; Rosen CJ; Chen P; Misurski DA; Marcus R
    Bone; 2006 Dec; 39(6):1268-75. PubMed ID: 16884968
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.